Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 11, 2024

Update on Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and CPIs

Annals of Oncology

 

Additional Info

Annals of Oncology
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
Ann. Oncol 2024 Jan 18;[EPub Ahead of Print], Y Loriot, DP Petrylak, AR Kalebasty, A Fléchon, RK Jain, S Gupta, M Bupathi, P Beuzeboc, P Palmbos, AV Balar, CE Kyriakopoulos, D Pouessel, CN Sternberg, J Tonelli, M Sierecki, H Zhou, P Grivas, P Barthélémy, ST Tagawa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading